Ivermectin vs. Albendazole for Chronic Strongyloidiasis
Author Information
Author(s): Suputtamongkol Yupin, Premasathian Nalinee, Bhumimuang Kid, Waywa Duangdao, Nilganuwong Surasak, Karuphong Ekkapun, Anekthananon Thanomsak, Wanachiwanawin Darawan, Silpasakorn Saowaluk
Primary Institution: Mahidol University, Bangkok, Thailand
Hypothesis
Is ivermectin more effective than albendazole for treating chronic strongyloidiasis?
Conclusion
Ivermectin, whether given as a single or double dose, is more effective than a 7-day course of high-dose albendazole for treating chronic strongyloidiasis.
Supporting Evidence
- Parasitological cure rates were 63.3% for albendazole, 96.8% for single-dose ivermectin, and 93.1% for double-dose ivermectin.
- No serious adverse events were reported in any treatment group.
- Patients were followed up for up to one year after treatment.
Takeaway
This study shows that taking ivermectin is better than taking albendazole for treating a type of worm infection called strongyloidiasis.
Methodology
A randomized, open-label study comparing a 7-day course of albendazole with single and double doses of ivermectin in patients with chronic strongyloidiasis.
Potential Biases
Potential bias due to the open-label design and loss to follow-up.
Limitations
High loss to follow-up rates and high mortality due to concomitant illnesses.
Participant Demographics
Adult patients with chronic strongyloidiasis, many with concomitant diseases.
Statistical Information
P-Value
0.006
Confidence Interval
95% CI 1.8–111.9 for ivermectin-I and 95% CI 1.3–25.7 for ivermectin-II compared to albendazole.
Statistical Significance
p=0.006
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website